Serotonin Syndrome Following Methylene Blue Administration for Vasoplegic Syndrome in Heart and Lung Transplantation – A Case Series


Abstract

Serotonin syndrome is a potentially life threatening adverse drug reaction caused by excessive activation of postsynaptic serotonin receptors in the central nervous system (CNS). It is typically associated with the simultaneous administration of two or more selective serotonin reuptake inhibitors (SSRI) or as a result of a combination with another drug with similar serotonergic activity. The authors describe two cases of intraoperative vasoplegic syndrome necessitating the use of methylene blue (MB) as rescue therapy and subsequently causing serotonin syndrome in the intensive care unit (ICU).

Keywords: Serotonin Syndrome; Vasoplegia; Methylene Blue; Cardiac Surgery; Transplant.

Introduction

Vasoplegic syndrome (VS) is a well-known form of vasodilatory shock that occurs after cardiac surgery employing cardiopulmonary bypass (CPB) [1]. Treatment of VS is primarily focused on high-dose vasopressor therapy. In addition to vasopressors, methylene blue (MB) proved to be of benefit for refractory VS in various studies [2-4]. The use of MB for VS carries a risk for the development of serotonin syndrome (SS).

SS is a potentially life threatening adverse drug reaction caused by excessive activation of postsynaptic serotonin receptors in the central nervous system (CNS) [5]. The syndrome is typically described as a clinical triad of mental status changes, autonomic instability and neuromuscular abnormalities [6]. It is difficult to diagnose particularly in the intensive care setting due to the potentially wide spectrum of presentation and overall physicians’ lack of familiarity with the disease.

The authors describe two cases of intraoperative VS necessitating the use of MB as rescue therapy, and subsequently causing SS in the ICU.

Case 1

The patient was a 64 year-old female with history of non-ischemic cardiomyopathy and left ventricular assist device (LVAD) in place undergoing orthotopic heart transplantation (OHT). Her comorbidities included atrial fibrillation (AF), monoclonal gammopathy, hypertension (HTN), asthma, osteoporosis, gastroesophageal reflux disease (GERD), and depression for which she was being treated with sertraline. She had recently been upgraded to a United Network for Organ Sharing (UNOS) status level 1A for LVAD malfunction. Following identification of an appropriate donor, she was taken to the operating room. Standard American Society of Anesthesiologists (ASA) monitors were placed.

A pre-induction arterial line was placed. Induction of general anesthesia was uneventful with midazolam, fentanyl, lidocaine, propofol and vecuronium for neuromuscular blockade. Subsequently a 9 French central venous catheter was placed in the right internal jugular vein through which a 7.5 French thermocatheter was placed as standard procedure for OHT at our institution. Following her transplant surgery, she was brought to the ICU with continuous infusions of several vasopressors as well as inotropes for refractory shock. She remained hypotensive despite large doses of vasopressors; therefore MB
was used for refractory VS. As the effects of general anesthesia subsided, there were no focal abnormalities recorded in her neurologic evaluation. When ondansetron was administrated for nausea, she progressively developed dilated pupils, ocular clonus, and diffuse muscle rigidity. She subsequently became febrile to 105.7 degrees Fahrenheit, with a bilateral ankle clonus on physical exam.

Delayed malignant hyperthermia and neuroleptic malignant syndrome were clinically ruled out, and serotonin syndrome was suspected. The patient's clinical history as well as pharmacologic treatment including sertraline, MB and ondansetron all implicated SS as a cause for her abnormal neurologic findings. The purported offending agents were discontinued, and she was treated symptomatically with cyproheptadine, acetaminophen, lorazepam and active cooling. Over the next several hours, her neurologic symptoms improved and her fever subsided. She experienced a full neurologic recovery, and was subsequently discharged home in stable condition.

Case 2

The patient was a 57 year-old female with history of interstitial lung disease on 5 liters per minute of continuous home oxygen therapy while at rest who presented for bilateral lung transplantation. Her comorbidities included diabetes mellitus type 2, GERD, degenerative disc disease and fibromyalgia for which she was being treated with duloxetine. Following identification of a suitable donor, bilateral lung transplantation was planned, with CPB as a backup for cardiovascular support.

After placement of standard ASA monitors, a pre-induction arterial line was placed in the left brachial artery. Induction of general anesthesia (GA) was uneventful using midazolam, lidocaine, fentanyl, propofol and rocuronium. Endotracheal intubation was performed with direct laryngoscopy using a Macintosh size 3 blade and a 37 French left-sided double lumen endotracheal tube and position confirmed with fiber optic bronchoscopy. Maintenance of general anesthesia was achieved using inhaled isoflurane as well as intermittent boluses of fentanyl and vecuronium for neuromuscular blockade. A 9 French central venous catheter was placed in the right internal jugular vein through which a continuous cardiac output pulmonary artery catheter placed using pressure waveform guidance. Following reperfusion of the transplanted lungs, the patient developed severe hypotension treated with continuous infusions as well as intermittent boluses of high-dose norepinephrine, vasopressin, and phenylephrine. At this point, due to refractory VS the decision was made to administer MB at a dose of 2mg/kg. Upon initial rapid administration of approximately half of the dose, the patient developed cardiac conduction abnormalities prompting slowing and eventual discontinuation of the medication. Subsequently, the patient’s hemodynamic parameters improved and vasopressor doses were deescalated.

She was transferred to the ICU in stable condition. Several hours later, the patient developed hyperthermia with maximum temperature of 105.7 degrees Fahrenheit; in addition she displayed neurologic findings of muscle rigidity, ankle clonus and papillary dilation. After ruling out other causes of perioperative hyperthermia, including malignant hyperthermia, as well as other potential neurologic catastrophes, the diagnosis of serotonin syndrome was made. Following the diagnosis, the patient was treated with supportive care including active cooling, as well as benzodiazepines for rigidity and clonus; cyproheptadine was considered but was not used due to the resolution of symptoms.

Discussion

Vasoplegic Syndrome

VS is a well-known form of vasodilatory shock that occurs in up to 44% of patients after cardiac surgery employing cardiopulmonary bypass (CPB) [1]. CPB is often associated with a systemic inflammatory response and transient vascular dysfunction that results in profound and persistent vasodilation. A decrease in systemic vascular resistance follows with severe hypotension, refractory to proper fluid resuscitation, and requiring an increased dose of vasopressors despite of high or normal cardiac outputs [7].

Although the exact mechanisms that lead to the development of VS are unknown, it is thought to be related to depletion of natural vasopressors during CPB [8], excessive complement activation [9], and the development of systemic inflammatory response syndrome (SIRS) [10, 11]. SIRS post cardiac surgery is believed to be induced by factors such as surgical trauma, changes in body temperature, blood exposure to non-physiologic surfaces, endotoxin release and ischemia-reperfusion of the myocardium [12, 13].

As blood passes through the CPB machine, plasma proteins are immediately absorbed to bio-membranes, generating a protein layer that is densely packed and immobile, with some proteins undergoing conformational changes [14, 15]. The result is the activation of the extrinsic and intrinsic coagulation pathway, the complement, and fibrinolytic pathways. In light of this, VS pathophysiology reflects a series of complex interactions among endothelial cells, plasma proteins, leukocytes, and platelets. Multiple factors including thrombin, C5a and cytokines, active endothelial cells produce vasoactive substances such as nitric oxide (NO) and prostacyclin that contribute to the persistent hypotension [16].

Blood transfused from the salvage mechanism (cell saver) contributes to the pathogenesis of vasoplegia, because of its hemolyzed erythrocytes, denatured proteins, fat globules and platelet and leukocyte aggregates which potentially stimulate and aggravate inflammatory responses. Additionally, an ischemia-reperfusion syndrome occurs after aortic cross clamp, causing neutrophils to adhere to endothelial cells with the release of free radicals causing direct damage to the tissues, and resulting in increased capillary permeability, interstitial edema and reduced intravascular volume [1].

This inflammatory response caused by CPB generates the formation of fibrin clots and micro emboli that leads to intraoperative myocardial ischemia and elevation of troponin I levels [12]. Nevertheless, the primary challenge in VS patients involves the management of severe hypotension induced by the vasodilatory effect of excessive NO production and decreased plasma levels of arginine vasopressin (AVP) [17]. Low vasopressin (VP) in plasma is attributed to decreased secretion due to an impaired baroreflex-mediated VP release, and to excessive secretion of VP with subsequent depletion of pituitary VP stores in the early stages of the inflammatory response [18, 19].
Treatment of VS is primarily focused on high-dose vasopressor therapy. In addition, MB has been used in various studies to show benefit for refractory VS [2-4]. It is thought to function by scavenging free nitric oxide (NO) as well as inhibiting endothelial synthesis of NO [20].

**Methylene Blue**

Although the mainstay treatment for VS is the use of high dose vasopressors, MB is recommended for refractory VS as rescue therapy [4]. MB inhibits vasodilation in different ways. One of the described mechanisms is the inhibition of constitutive and inducible NO synthase [21, 22]. Another mechanism is through the inhibition of guanylyl cyclase which is an important catalyst in vasodilation mediated by NO (Figure 1). MB has been associated with developing SS, especially in patients undergoing cardiothoracic surgery and taking SSRI [23]. MB is a potent and reversible Monoamine Oxidase A (MAO-A) inhibitor, which prevents serotonin metabolism. Several studies have described that MB exerts higher inhibitory effects on MAO-A than MAO-B, probably due to its wider active site [23, 24].

SS is rarely described in patients taking a mono-serotonergic therapy. However, this condition may be precipitated by adding a single dose of MB. The Food and Drug Administration (FDA) recommends for patients who are at risk to be exposed to MB to stop taking serotonergic agents at least 2 weeks prior to its potential administration [25, 26].

**Serotonin Syndrome**

Serotonin Syndrome (SS) is a life-threatening adverse drug reaction caused by the excess of serotonin activity in the central and peripheral nervous systems [27]. It is typically associated with the simultaneous administration of two or more selective SSRI or as a result of a combination with another drug with similar serotonergic activity. The addition of drugs that inhibit the cytochrome P450 2D6 or 3A4 isoenzymes to an ongoing therapy regimen of an SSRI have been reported [28]. Likewise, different classes of drugs including anesthetics have been implicated in the development of SS. It is important to mention that serotonergic agents may include nonprescription drugs, illicit drugs, and diet supplements (Table 1) [27].

Clinically, SS is characterized by a triad of neuromuscular abnormalities (tremor, clonus, myoclonus, and hyperreflexia), autonomic hyperactivity (diaphoresis, fever, tachycardia, tachypnea, and mydriasis), and mental status changes (agitation and confusion) [29]. Interestingly, SS has been reported in all age groups [30]. Symptoms can develop within a few minutes of drug ingestion; however, the most common onset of SS symptoms was reported within 6 to 24 hours from the moment of the purported drug administration [27]. The incidence of SS is certainly unknown. Nonetheless, it is believed that the incidence is rising due to the recent surge of serotonergic medications prescribed in the clinical setting, specifically with a high predominance in females [30]. Furthermore, SS has been reported in patients with end stage renal disease under treatment with an SSRI in combination with Monoamine Oxidase Inhibitors (MAOis) [28]. Frequently, this condition is undiagnosed or under recognized among physicians and may have serious clinical complications, such as metabolic acidosis, rhabdomyolysis, seizures, renal failure, and disseminated intravascular coagulopathy [31].

SS is entirely a clinical diagnosis, principally based on patient's history and physical examination. Laboratory studies may provide an insight of serious complications or help rule out other diagnoses [30]. Hunter's criteria for serotonin toxicity are the most extensively used for the diagnosis of SS, with a sensitivity of 84% and a specificity of 97% [32]. The diagnosis is established if the patient is taking a serotonergic agent and presents any of the following symptoms: spontaneous or inducible clonus plus agitation or diaphoresis, ocular clonus, tremor with hyperreflexia, and hypertonia plus hyperthermia (>101.3°F) plus ocular clonus or inducible clonus [28], as reported in our two cases.

The differential diagnoses for SS include malignant hyperthermia, neuroleptic malignant syndrome (NMS), and anticholinergic syndrome. Sometimes, SS can be distinguished from other diagnoses by the patients’ symptomatology, onset of symptoms, and medication use. Remarkably, patients with SS may experience overlapping symptoms of NMS when causative drugs have been admin-

---

**Figure 1. Inhibition of Nitric Oxide-Mediated Vasodilation by Methylene Blue.**
Serotonin Syndrome is a life-threatening condition characterized by the overactivity of serotonin neurons. It can occur in response to the administration of medications that increase serotonin levels, such as tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), and serotonin agonists. The symptoms of SS include agitation, tremors, hyperthermia, autonomic instability, and severe changes in blood pressure. Treatment involves discontinuing the causative agents, administration of serotonin antagonists like cyproheptadine, and supportive therapies such as cooling and sedation.

### References


